SHL Telemedicine .(SHLT) - 2022 Q4 - Annual Report

Financial Reporting and Compliance - SHL Telemedicine's financial statements are prepared in accordance with IFRS and reported in U.S. dollars[13] - The company faces risks related to compliance with complex healthcare regulations, which could adversely affect its operations and financial condition[23] - The company may face challenges in complying with tax laws across multiple jurisdictions, which could impact its financial condition if tax policies are challenged[70] - The company is exempt from certain public disclosure requirements as a foreign private issuer, which may afford less protection to ADS and ordinary share holders[85] - The company is classified as an "emerging growth company," which may make its securities less attractive to investors due to reduced disclosure requirements[89] - The deposit agreement for ADS holders may be amended or terminated without their consent, potentially affecting their rights[92] Market and Competitive Landscape - The telehealth market is rapidly evolving, with significant competition leading to pricing pressures and potential impacts on sales and profitability[34] - The company faces significant competition in the telemedicine market, with competitors including GE Healthcare, Medtronic, and Philips Medical Systems, which have greater resources and established brands[166] - The competitive landscape includes pressures from both large companies and smaller startups, leading to potential pricing declines in certain product segments[163] - Recent legislative changes in Germany have accelerated the adoption of telemedicine services, with expectations for a significant market shift towards remote medical services[152] Business Operations and Strategy - The company acquired a 70% interest in the Mediton Group on August 31, 2021, enhancing its market presence[16] - SHL Telemedicine is focused on continuous product development and enhancements to meet customer needs and market demands[32] - The company aims to improve users' quality of life and reduce emergency interventions through its telemedicine solutions[104] - SHL has strategically acquired local companies in Germany, enhancing its position in the telehealth market and remote patient monitoring services[105] - SHL is actively seeking to enhance growth through selective acquisitions and cross-selling opportunities, including potential targets in telemedicine[141] Financial Performance - SHL's revenue for the year ended December 31, 2022, was $58,998,000, representing a 19% increase from $49,582,000 in 2021[193] - Gross profit for 2022 was $27,189,000, up from $24,593,000 in 2021, indicating a growth of 10.6%[193] - Operating expenses increased to $32,355,000 in 2022 from $25,090,000 in 2021, reflecting a rise of 28.9%[193] - The net profit for 2022 was $215,000, a significant recovery from a net loss of $13,924,000 in 2021[193] - SHL's operating loss for 2022 was $5,166,000, compared to a loss of $497,000 in 2021, indicating ongoing challenges in profitability despite revenue growth[193] Risks and Challenges - The ongoing COVID-19 pandemic presents operational challenges, including increased logistics costs and labor market competition[37] - Retaining key personnel is critical for SHL's growth strategy, with intense competition for skilled employees in the healthcare sector[40] - Military instability and political conditions in Israel may adversely affect the company's business and operations[44] - Labor disputes could disrupt operations or lead to higher labor costs, significantly impacting financial performance[58] - The company is exposed to operational risks due to differing legal and regulatory requirements in international markets[56] - The company is dependent on third-party suppliers and manufacturers, which may lead to logistical problems and affect product quality[61] - The company is exposed to data security and privacy risks, with potential impacts from cyberattacks and system breaches[65] - Fluctuations in exchange rates may affect the company's financial results, as revenues and expenses are paid in multiple currencies[66] Product Development and Innovation - SHL's patented SmartHeart® platform was introduced in the US in 2020, leading to commercial agreements with major healthcare providers like Mayo Clinic and CVS[106] - The SmartHeart® platform is a key product, being the only full ECG 12 lead ECG that can be performed by a layperson, and is FDA-cleared and patented[177] - The introduction of remote monitoring reimbursement by G-BA in early 2022 has established telemonitoring for congestive heart failure patients as the standard of care[137] - SHL's SmartHeart® platform is marketed to healthcare providers and payers in the US, with collaborations including the Mayo Clinic and CVS Health[162] Shareholder Information - As of May 5, 2023, certain principal shareholders hold approximately 36.4% of the issued shares of SHL, which may influence shareholder decisions if restrictions are lifted[73] - The market prices of the company's ADSs on Nasdaq and ordinary shares on the SIX may be highly volatile, influenced by economic conditions and geopolitical factors[75] - The company has not declared dividends since 2019, with no assurance of future dividends impacting shareholder returns[82] - The trading prices of the company's ADSs and ordinary shares may decline due to substantial future sales or perceived sales of equity securities[77]